The tweet was deleted by the author.
But we saved everything 🙂.
Castle Biosciences has announced new research showing its TissueCypher Barrett Esophagus Test prompted clinicians to alter their management recommendations in 90 percent of cases involving patients with non-dysplastic Barrett esophagus (NDBE).
The company highlighted that the findings support the test’s role in promoting more risk-aligned management for patients with this condition.
View post on X Loading...
Earlier this year, Castle Biosciences published a multi-center study validating the accuracy of its DecisionDx-SCC test for high-risk squamous cell carcinoma patients, according to company data. The company also expanded its operational footprint with a new laboratory and office facility in Scottsdale, Arizona opened recently. These developments mark continued activity in Castle Biosciences’ diagnostic and infrastructure initiatives.